Sale of Genzyme is possible if the price is right, CEO says

09/1/2010 | Bloomberg

Genzyme CEO Henri Termeer said he will consider putting the biotech company up for sale if the price is right. Termeer said he will oppose Sanofi-Aventis' unsolicited offer of $18.5 billion, or $69 per share, because such an offer underestimates Genzyme's portfolio of experimental drugs.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ